FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年8月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年8月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不 ...

丽珠医药(01513)发布公告，于2025年8月28日斥资493.1万元回购12.34万股A股。 ...

格隆汇8月28日丨丽珠医药(01513.HK)公告，8月28日耗资493.1万元回购12.3万股A股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年8月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不 ...

麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* (a joint stock company incorporated in the People's Republic of China with limited liability) 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 (Stock code 股份代號: 1513) NOTIFICATION LETTER 通知信函 29 August 2025 Dear Non-Registered Holder(Note 1), Livzon Pharmaceutical Group Inc.(the "Company") Notification of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are av ...

麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* (a joint stock company incorporated in the People's Republic of China with limited liability) 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 (Stock code 股份代號: 1513) NOTIFICATION LETTER 通知信函 29 August 2025 Dear Registered Shareholder, Livzon Pharmaceutical Group Inc. (the "Company") Notification of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now av ...

目錄 備查文件目錄 2 財務摘要 3 第一節 重要提示和釋義 5 第二節 公司簡介和主要財務指標 11 第三節 管理層討論與分析 16 第四節 公司治理 66 第五節 重要事項 69 第六節 股份變動及股東情况 70 第七節 財務報告 81 備查文件目錄 2 麗珠醫藥集團股份有限公司 二零二五年中期報告 （一） 載有公司負責人、主管會計工作負責人、會計機構負責人（會計主管人員）簽名並蓋章的按照《中 國企業會計準則》編制的截至2025年6月30日止六個月的未經審計的財務報表。 （二） 本報告期內公開披露過的所有本公司文件的正本及公告的原稿。 （三） 在香港交易及結算所有限公司網站公佈的本公司2025年H股半年度報告英文版和中文版。 財務摘要 -0.17% 9.40% 8.91% 10.26% 13.66% 1,170.97 6,282.35 1,281.09 6,271.91 1,155.47 1,258.46 1,530.03 1,686.94 1,608.39 1,828.11 主要財務指標（人民幣百萬元） 營業收入 歸屬於本公司股東 利潤總額 的淨利潤 歸屬於本公司股東的 扣除非經常性損益 經營活動產生的 ...

Group 1: Changan Automobile (000625) - In H1 2025, Changan Automobile achieved revenue of 72.691 billion yuan, a decrease of 5.25% year-on-year, while the net profit attributable to shareholders was 2.291 billion yuan, down 19.09%. However, the net profit excluding non-recurring items increased by 26.36% to 1.477 billion yuan [6][7] - In Q2 2025, the company reported a net profit of 939 million yuan, a decrease of 43.93% year-on-year, while the net profit excluding non-recurring items was 693 million yuan, down 34.40% year-on-year. Revenue for the quarter was 38.531 billion yuan, showing a slight decrease of 2.94% quarter-on-quarter but a 12.79% increase year-on-year [7] - The company plans to launch three new models in Q4 2025, with a clear strategy for global expansion, aiming for overseas sales of 1 million vehicles by the end of the year [8][9] Group 2: Sailun Tire (601058) - In H1 2025, Sailun Tire achieved revenue of 17.587 billion yuan, a year-on-year increase of 16.05%, but the net profit decreased by 14.90% to 1.831 billion yuan. In Q2 2025, revenue was 9.175 billion yuan, up 16.76% year-on-year, while net profit fell by 29.11% to 792 million yuan [10][11] - The company benefited from overseas market expansion, with tire production reaching 40.6 million units in H1 2025, a 14.66% increase year-on-year, and sales of 39.14 million units, up 13.32% [11] - Sailun Tire is focusing on enhancing its international influence through increased R&D investment and product innovation, with a notable presence in the global tire brand value rankings [11][12] Group 3: Xinjieneng (605111) - In H1 2025, Xinjieneng reported revenue of 930 million yuan, a year-on-year increase of 6.44%, and a net profit of 235 million yuan, up 8.03%. The net profit excluding non-recurring items was 207 million yuan, down 3.22% [14][15] - The SGT MOS product line's revenue share increased to 45.21%, indicating strong market competitiveness and application in various strategic fields [16] - The company is focusing on emerging markets such as automotive electronics, AI servers, and robotics, with significant growth in these areas expected [17] Group 4: Lizhu Group (000513) - In H1 2025, Lizhu Group achieved revenue of 6.272 billion yuan, a slight decrease of 0.17%, while net profit increased by 9.40% to 1.281 billion yuan. The net profit excluding non-recurring items was 1.258 billion yuan, up 8.91% [22][23] - The company is experiencing growth in its chemical preparation segment, with a focus on new product launches and improved operational efficiency [23][24] - Multiple products are entering the harvest phase, contributing to the overall positive performance [24] Group 5: Anhui Heli (600761) - In H1 2025, Anhui Heli reported revenue of 9.39 billion yuan, a year-on-year increase of 6.18%, with net profit reaching 796 million yuan, down 4.60%. Overseas revenue was 4.016 billion yuan, up 15.20% [27][28] - The company is enhancing its international presence with a new overseas manufacturing facility and a strong network of over 300 overseas agents [28] - Anhui Heli is focusing on electric and intelligent logistics solutions, with significant growth in electric vehicle sales and strategic partnerships in the logistics sector [29][30] Group 6: Domestic Industrial Profit Data - In July 2025, the total profit of industrial enterprises above designated size decreased by 1.7% year-on-year, showing a slight improvement from the previous month's decline of 1.8% [32][33] - The report indicates that the "anti-involution" policy is affecting profit structures across various sectors, with upstream raw material manufacturing seeing a recovery in profit margins [34] - Inventory levels are decreasing, with nominal inventory growth slowing to 2.4% year-on-year, indicating a reduction in production and a passive consumption of inventory [35] Group 7: Mechanical Equipment Industry - In July 2025, the overall sales of forklifts reached 118,600 units, a year-on-year increase of 14.4%, with both domestic and overseas sales showing double-digit growth [36][37] - The growth in forklift demand is linked to improvements in manufacturing and logistics sectors, with positive macroeconomic indicators supporting future sales [38] - Companies like Anhui Heli and Hangcha Group are expanding their global presence and enhancing their product offerings in intelligent logistics [39][40]

Overview - Tryptophan is an essential amino acid that cannot be synthesized by the human body and must be obtained through food [2][4] - The market demand for tryptophan has rapidly increased due to the development of the livestock industry and the "reduction of soybean meal substitution" policy [4][9] - In 2024, the demand for tryptophan in China is projected to reach 23,800 tons, with a market size of 1.309 billion yuan [4][9] Market Policy - The Chinese government has issued several policies to support the development of the amino acid industry, including the "14th Five-Year Plan" and various guidelines for the pharmaceutical and feed industries [4][5] Industry Chain - The upstream of the tryptophan industry includes suppliers of raw materials like corn and molasses, while the midstream involves the production of tryptophan, and the downstream encompasses applications in feed, pharmaceuticals, health products, and food [6][7] Current Development - The feed sector accounts for over 70% of the demand for tryptophan in China, with industrial feed production expected to reach 158.5 million tons in the first half of 2025, a year-on-year increase of 7.7% [9][10] - The increasing focus on health foods has led to a rise in the use of tryptophan as a nutritional supplement for improving sleep and emotional balance [4][9] Competitive Landscape - The market concentration of tryptophan has increased, with international companies like Ajinomoto and CJ Cheiljedang holding significant market shares, while domestic companies such as Ningxia Yipin Biotechnology and Anhui Huaheng Biological Technology are gaining ground through innovation and resource advantages [10][11] Key Players - Fujian Group is a major player in the tryptophan market, with projected revenues of 27.76 billion yuan and a gross profit of 5.057 billion yuan in 2024 [12] - Anhui Huaheng Biological Technology focuses on synthetic biology and expects revenues of 2.178 billion yuan in 2024, with amino acid products contributing 69.28% of total revenue [12][13] Future Trends - The production of tryptophan is primarily through microbial fermentation, with future advancements expected in genetic engineering to enhance production efficiency and product purity [14] - There is a growing emphasis on green production processes to reduce costs and environmental impact, aligning with stricter environmental regulations [14]